CCP's first SARS-CoV-2 vaccine patented. German experts: Vaccines may not have long-term effect

 Reporter: Liming / Editor: Ming Xuan / Publisher : New Tang Dynasty Television

Ref : https://www.ntdtv.com/gb/2020/08/17/a102920107.html 

Translation, editing : Gan Yung Chyan, KUCINTA SETIA

Chinese mainland media recently disclosed that the vaccine developed by the Chinese military research team and Cansino Biotechnology against covid has obtained a nationally confirmed patent. Enter the third phase of testing. However, German researchers not long ago pointed out that people who have recovered from covid do not have long-term immunity, which means that related vaccines may not have long-term effects.

Mainland China media CBN recently reported that the State Intellectual Property Office of China has issued an announcement that a team led by Chen Wei, a member of the Academy of Military Medicine of the Academy of Military Sciences, and "CanSino Bio" jointly developed a new type of SARS-CoV-2 vaccine named Ad5-nCoV. The vaccine patent application was filed on 18 March 2020 and the patent was granted on 11 August 2020. The vaccine is currently undergoing Phase III clinical trials.

Earlier, at the beginning of the large-scale outbreak of the virus in Wuhan, Chen Wei led a group of medical experts from Harbin Veterinary Research Institute to Wuhan Institute of Viology on 26 January and announced that it would start research on related vaccine antibodies. On 16 March, the team announced the completion of the vaccine development and was approved to officially enter the Phase 1 clinical trial. On 12 April, the Phase 2 clinical trial began again, and 508 people received the vaccine.

Just before the news that the vaccine was patented, people on the Chinese Internet began to sell the vaccine at the price of 498 RMB. Although the relevant pharmaceutical company later issued a statement confirming that the online community was selling fake vaccines, a Chinese media reported on the 17th that a pharmaceutical company in Beijing had privately indicated to organizations and organizations in need that it could provide a SARS-CoV-2 vaccine. The cost is 1,000 RMB for 2 stitches.

In response to the above rumours, mainland China media’s "21st Century Business Herald" also reported recently that some employees in Beijing's medical service industries and companies that need to go abroad have been vaccinated with Ad5-nCoV vaccine and "signed a confidentiality agreement." Some vaccinators revealed that the pharmaceutical company claimed that the effective time of this SARS-CoV-2 vaccine "in theory" is 5 to 6 years, but it did not say how protective the vaccine can be.

Immediately, Chinese national defense experts spoke out, urging the public not to be "too anxious," saying that the vaccine is still undergoing the third phase of testing and it will take another three months to see how effective the vaccine is.

However, just a month ago, the results of a blood study of recovered patients conducted by German researchers showed that the Chinese virus vaccine may not produce long-term effects.

Clemens Wendtner, Director of Infectious Disease Department at München Klinik Schwabing Hospital in Munich, Germany, released a research report in mid-July, referring to the research team’s assessment of the first batch of 9 patients treated in the hospital at the end of January this year. The blood of COVID-19 patients recovered from SARS-CoV-2 infection was tested, and it was found that after a period of time, the amount of neutralizing antibodies in the blood of the person involved decreased significantly. This means that even if the person involved has developed immunity to the virus, he may still lose this immunity after a period of time.

Dr. Ventner said that in terms of long-term immunization and vaccine strategies, the impact of this discovery can only be guessed at present, but it must be closely observed. He emphasized that this situation reminds people that survivors are not able to obtain long-term immunity and may still be infected again. Therefore, it is difficult to expect vaccines to have long-term effects on the human body.

Coincidentally, Chinese researchers have also found similar observations.

A research report published by a Chinese scientific researcher in the professional journal "Nature Medicine" pointed out that two months after covid patients were cured, especially in asymptomatic patients, the number of antibodies decreased significantly, with some mild symptoms and patients have fewer antibodies.